Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Senzime AB ( (SE:SEZI) ).
Senzime AB has announced that the Japanese Society of Anesthesiology has updated its clinical guidelines to require quantitative neuromuscular monitoring during anesthesia, which is expected to boost the adoption of Senzime’s TetraGraph system in Japan. With the new guidelines aligning with global trends and Senzime’s existing installations in Japanese hospitals, the company anticipates increased utilization of its monitoring systems, potentially improving patient outcomes and expanding its market presence in Japan.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company based in Uppsala, Sweden, established in 1999. It specializes in precision-based monitoring systems that enhance perioperative patient safety and outcomes. The company’s flagship product, the TetraGraph® system, is renowned for its accuracy in monitoring neuromuscular transmission during surgery. Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 498,714
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.02B
Learn more about SEZI stock on TipRanks’ Stock Analysis page.